Kerry Group Expands Cork Facility
Analysis based on 6 articles · First reported Apr 20, 2026 · Last updated Apr 21, 2026
The expansion of Kerry Group's biotechnology facility is expected to positively impact the company's stock performance due to increased capacity and market share in the growing lactose-free dairy sector. It also strengthens Republic of Ireland's position in advanced food manufacturing and biotechnology, potentially attracting further investment.
Kerry Group has officially opened an expanded biotechnology manufacturing facility in Carrigaline, Co Cork, significantly increasing its capacity to produce lactase enzymes. This investment by Kerry Group aims to meet the rising global demand for lactose-free and reduced-sugar dairy products. The upgraded site will enable Kerry Group to scale production more quickly, ensuring consistent supply for dairy producers worldwide. Shane McGibney, President and CEO of Biotechnology Solutions and Transformation at Kerry Group, noted that this development is a key step in translating research into commercial capability. Peter Burke, Republic of Ireland's Minister for Enterprise, Tourism and Employment, highlighted the investment's role in supporting Republic of Ireland's food and biotech sectors. Ronan Moloney, Vice President of Enzymes at Kerry Group, stated that the increased capacity will help reduce bottlenecks and strengthen supply continuity for customers. The Carrigaline site currently supports over 200 customers across more than 80 countries, processing over two million tonnes of milk annually.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard